Toggle light / dark theme

The Nitazoxanide Plus Atazanavir for COVID-19 Study

In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19.

One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans.

The FDA issued an E… See More

The nitazoxanide plus atazanavir for COVID-19 study — full text view.


Since the outbreak of the novel coronavirus disease in 2019 (COVID-19), an unprecedented global search for potential therapeutics and vaccines is ongoing. In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19. One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans.

In this pilot study, 98 COVID-19 patients will be recruited into two group. The 49 patients in group 1 will receive the standard of care determined by their primary care providers while the 49 patients will receive both the standard of care combined with the two study drugs. Patients in group 2 will receive the study drugs for 14 days and all patients will be monitored for a total of 28 days.

Special Edition Mini-Cast: Preview of the 2020 Ending Age-Related Diseases Conference

Keith Comito, president of Life Extension Advocacy Foundation, joins me for a discussion to preview the 2020 Eding Age Related Diseases conference, to be held online, August 20–21, 2020. Go HERE to register for the conference, and use discount code SeekingDelphiEARD

You can subscribe to Seeking Delphi™ on Apple podcasts, PlayerFM, MyTuner, Listen Notes, and YouTube. You can also follow us on twitter @Seeking_Delphi and Facebook.

New device delivers single cells in just one click

EPFL spin-off SEED Biosciences has developed a pipetting robot that can dispense individual cells one by one. Their innovation allows for enhanced reliability and traceability, and can save life-science researchers time and money.

The engineers at SEED Biosciences, an EPFL spin-off, have come up with a unique pipetting robot that can isolate single with the push of a button—without damaging the cells. Their device also records the cells’ electrical signature so that they can be traced. While this innovation may seem trivial, it can save researchers several weeks of precious time and speed up development work in pharmaceuticals, cancer treatments and personalized medicine. The company began marketing its device this year.

The No. 1 colostrum company in Vietnam help people strengthening the immune system to contribute fighting off COVID-19

Vietnam has been one of the countries that have well managed COVID-19 pandemic with only 383 cases, and no deaths have been reported (updated on 20th July). Immune Nutrition from ColosIgG 24h colostrum is one of the factors contribute fighting off COVID-19 in VietnamnnPrior to this pandemic, being aware that strengthening the immune system is very important for health, especially for children, the Vietnamese Ministry of Health cooperated with VitaDairy Company to organise a series of seminars on Immune Nutrition in big cities. As a result, at the end of 2019 when the COVID-19 outbreak started, people understood the importance of the immune system and the value of immune nutrition from ColosIgG 24h colostrum.nn


P rior to this pandemic, being aware that strengthening the immune system is very important for health, especially for children, the Vietnamese Ministry of Health cooperated with VitaDairy Company to organise a series of seminars on Immune Nutrition in big cities. As a result, at the end of 2019 when the COVID-19 outbreak started, people understood the importance of the immune system and the value of immune nutrition from ColosIgG 24h colostrum. In addition to the seminars, Vietnamese Ministry of Health has taken many quick and appropriate actions to deal with the pandemic. Thanks to these actions, up to now, Vietnam is one of the countries that have very well managed the COVID-19 pandemic.

VitaDairy As The Ministry of Health’s Partner — “With Competence And A Strong Will”

In parallel with the seminar series, VitaDairy became the No. 1 colostrum company in Vietnam while making a hundred million dollar deal with the leading colostrum group in the US — PanTheryx — to exclusively import ColosIgG 24h colostrum to Vietnam. Joining hands to combat the pandemic, VitaDairy donated 1 million ColosIgG 24h colostrum products to the Vietnamese people and donated protective equipment to health workers with a total sponsorship of nearly 500,000 USD.

Diabetes Drug Candidate Could Offer “Distinct and Innovative” Treatment For Type 1 and Type 2 Disease

Researchers at the University of Alabama at Birmingham, and Southern Research, have identified a new drug candidate that they claim could represent a “distinct and innovative” approach to treating type 1 and type 2 diabetes. The small molecule drug, designated SRI-37330, inhibits the expression of a protein known as TXNIP—which the team had previously identified as a top glucose-induced gene—in both mouse and human islets.nnResults from the researchers’ preclinical studies suggested that SRI-37330 acts on pancreatic islet cells that produce glucagon and insulin, and also acts on the liver. The findings showed that the drug could have therapeutic effects against diabetes, in both lean and obese individuals. Tests on isolated human and mouse pancreatic islets, on mouse and rat cell cultures, and in animal models of both type 1 and type 2 diabetes, demonstrated that SRI-37330 improved diabetes-related hyperglycemia, and hyperglucagonemia; reduced the excessive production of glucose by the liver; and reduced fatty liver, or hepatic steatosis.nn


Studies showed non-toxic, orally bioavailable small molecule effectively rescued mice from models of type 1 and type 2 diabetes, and reduced fatty liver.

Tesla Has Been Working On an RNA Bioreactor

Tesla and CureVac have collaborated on a patent for an RNA bioreactor.

Although there are no human vaccines made with RNA, the technology could break through on COVID-19 (coronavirus).

The bioreactor works by combining chemical agents in an egg-shaped magnetic mixer.


Tesla has taken on the manufacturing role for a biotech startup with a revolutionary new RNA reactor concept. A tipster recently alerted Electrek to this year-old patent application, which lists both Tesla and German startup CureVac.

CureVac has made the news recently because of a misinformed factoid that it was being purchased by President Donald Trump. That’s partly because CureVac is working on the groundwork for a COVID-19 (coronavirus) vaccine. Today, the European Investment Bank (EIB) reported that it’s awarded an $84 million loan to CureVac to accelerate that vaccine development process.